Xenetic Biosciences (XBIO) Enterprise Value (2011 - 2026)
Xenetic Biosciences' (XBIO) quarterly Enterprise Value came in at -$7.3 million in Q1 2026, down 42.29% YoY from -$12.7 million in Q1 2025, and up 6.8% on a QoQ basis from -$7.9 million in Q4 2025.
Xenetic Biosciences (XBIO) Enterprise Value (2011 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 16 years of Enterprise Value data on file, last reported at -$7.3 million in Q1 2026.
- Quarterly Enterprise Value fell 42.29% year-over-year to -$7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.3 million (down 42.29% YoY) and the FY2025 annual result came in at -$7.9 million, down 27.87% from the prior year.
- Enterprise Value grew to -$7.3 million in Q1 2026, from -$7.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$4.1 million in Q3 2025 to a low of -$16.2 million in Q1 2022.
- A 5-year average of -$9.2 million and a median of -$7.9 million in 2025 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value plunged 61.43% — and 2025, when it surged 39.74%.
- Tracing XBIO's Enterprise Value over 5 years: stood at -$13.1 million in 2022, then jumped by 31.41% to -$9.0 million in 2023, then surged by 31.36% to -$6.2 million in 2024, then fell by 27.87% to -$7.9 million in 2025, then increased by 6.8% to -$7.3 million in 2026.
- The last three Enterprise Value figures came in at -$7.3 million (Q1 2026), -$7.9 million (Q4 2025), and -$4.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Xenetic Biosciences | 7.59 Mn | 1.12 Mn | - | -6.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.47 Mn |
| Mar 31, 2026 | -7.35 Mn |
| Dec 31, 2025 | -7.88 Mn |
| Sep 30, 2025 | -4.12 Mn |
| Jun 30, 2025 | -4.78 Mn |
| Mar 31, 2025 | -5.16 Mn |
| Dec 31, 2024 | -6.17 Mn |
| Sep 30, 2024 | -6.84 Mn |
| Jun 30, 2024 | -7.30 Mn |
| Mar 31, 2024 | -7.82 Mn |
| Dec 31, 2023 | -8.98 Mn |
| Sep 30, 2023 | -9.78 Mn |
| Jun 30, 2023 | -10.73 Mn |
| Mar 31, 2023 | -11.99 Mn |
| Dec 31, 2022 | -13.10 Mn |
| Sep 30, 2022 | -13.85 Mn |
| Jun 30, 2022 | -14.93 Mn |
| Mar 31, 2022 | -16.16 Mn |
| Dec 31, 2021 | -18.24 Mn |
| Sep 30, 2021 | -19.70 Mn |